This week: Bionic Pancreas in Type 1 Diabetes and Weekly Dalbavancin for Skin Infections
Travis and Amol want you to:
1. Understand the potential role of a novel bionic pancreas in glycemic control in type 1 diabetes.
2. Recognize that dalbavancin is non-inferior to vancomycin/linezolid in treating skin infections and represents a potentially revolutionary once weekly approach to treating serious infections.
Continuing Medical Education
Internists can receive 0.5 hours of Continuing Medical Education credit for each podcast they listen to through the Canadian Society of Internal Medicine (MOC Category 1) and the American Medical Association (PRA Category 1). To receive CME credit for listening to this podcast, please click here to fill out our Evaluation and Impact Assessment Form.
The papers
Steven J. Russell et al. Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes. N Engl J Med. Published online June 15, 2014. (PubMed).
A picture of the bionic pancreas can be seen in the supplementary materials here.
Helen W. Boucher et al. Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection. N Engl J Med 2014; 370:2169-2179. (PubMed).
Good stuff
Travis:
David van Dijk et al. Publication metrics and success on the academic job market. Curr Biol 2014 Jun 2;24(11):R516-7. (PubMed).
Amol:
The Medical Reformation, Richard Lehman, BMJ Group Blogs, Jun 6, 2014.
